GGrantIndex
← Leaderboards

Donna M. Wilcock

Duke University

Google Scholar ↗PubMed ↗ORCID ↗
$23,783,452
Attributed
$29,367,947
Total exposure
16
Grants
14
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.4M · FY2007–25
$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$32,702,963 · 17

By mechanism

R01$7,553,618 · 4
UF1$6,120,000 · 1
P30$4,553,847 · 3
RF1$3,627,180 · 2
UH3$3,405,574 · 1
U54$3,335,016 · 1

Top collaborators

Most similar at Duke University

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposS DiseaseDementiaBrainMagnetic Resonance ImagingPathologyImageImpaired CognitionMouse ModelProteinsPlasmaBiological MarkersVascular Cognitive Impairment And DementiaUniversitiesAstrocytesCerebrovascular DisordersCohortInflammationInflammatoryBlood VesselsResponseKentuckyAutopsyHyperhomocysteinemia

Grant awards (47)

Microphysiological systems to Advance Precision medicine for Alzheimer's Disease and Related Dementias (MAP-AD)$3,335,016
U54 · FY2025 · AG
Project 1 - Astrocytic end-feet and VCID$535,200
P01 · FY2025 · AG · contact PI
Establishing the role of MMP9 in amyloid-immunotherapy-induced ARIA$510,498
R01 · FY2025 · NS · contact PI
Genetic, Biomarker and Biospecimen Core$342,877
P30 · FY2025 · AG · contact PI
Investigating Neurosciences, a Summer Program to Ignite Research and Education (INSPIRE)$215,998
R25 · FY2025 · AG
Elucidating the role of placental growth factor in diffuse white matter disease$601,832
R01 · FY2024 · NS · contact PI
Project 1 - Astrocytic end-feet and VCID$591,611
P01 · FY2024 · AG · contact PI
Core F: University of Kentucky Alzheimer's Disease Core Center$539,319
P30 · FY2024 · AG · contact PI
Genetic, Biomarker and Biospecimen Core$347,216
P30 · FY2024 · AG · contact PI
The University of Kentucky MarkVCID Biomarker Validation Cohort: Development of a Toolbox to Advance VCID Interventional Studies$3,672,000
UF1 · FY2023 · NS
Project 1 - Astrocytic end-feet and VCID$591,611
P01 · FY2023 · AG · contact PI
Core F: University of Kentucky Alzheimer's Disease Core Center$566,473
P30 · FY2023 · AG · contact PI
Elucidating the role of placental growth factor in diffuse white matter disease$482,202
R01 · FY2023 · NS · contact PI
Elucidating the role of placental growth factor in diffuse white matter disease$103,437
R01 · FY2023 · NS · contact PI
Establishing the role of MMP9 in amyloid-immunotherapy-induced ARIA$1,388,218
RF1 · FY2022 · NS · contact PI
Elucidating the role of placental growth factor in diffuse white matter disease$697,777
R01 · FY2022 · NS · contact PI
Core F: University of Kentucky Alzheimer's Disease Core Center$594,829
P30 · FY2022 · AG · contact PI
Project 1 - Astrocytic end-feet and VCID$591,611
P01 · FY2022 · AG · contact PI
Establishing the role of MMP9 in amyloid-immunotherapy-induced ARIA$360,647
RF1 · FY2022 · NS · contact PI
The University of Kentucky MarkVCID Biomarker Validation Cohort: Development of a Toolbox to Advance VCID Interventional Studies$2,448,000
UF1 · FY2021 · NS
Elucidating the role of placental growth factor in diffuse white matter disease$716,156
R01 · FY2021 · NS · contact PI
Core F: University of Kentucky Alzheimer's Disease Core Center$624,580
P30 · FY2021 · AG · contact PI
Neurovascular astrocyte dysfunction in VCID$374,815
R01 · FY2021 · NS · contact PI
Small vessel disease biomarkers in a longitudinally-followed "stroke-belt" cohort$1,125,772
UH3 · FY2020 · NS · contact PI
Elucidating the role of placental growth factor in diffuse white matter disease$741,549
R01 · FY2020 · NS · contact PI
University of Kentucky Alzheimer's Disease Core Center - Biomarker Core$564,265
P30 · FY2020 · AG · contact PI
Neurovascular astrocyte dysfunction in VCID$375,080
R01 · FY2020 · NS · contact PI
Small vessel disease biomarkers in a longitudinally-followed "stroke-belt" cohort$1,135,298
UH3 · FY2019 · NS · contact PI
University of Kentucky Alzheimer's Disease Core Center - Biomarker Core$491,734
P30 · FY2019 · AG · contact PI
Neurovascular astrocyte dysfunction in VCID$375,345
R01 · FY2019 · NS · contact PI
Therapeutic targeting of TREM2 for Alzheimer's disease$1,878,315
RF1 · FY2018 · AG · contact PI
Small vessel disease biomarkers in a longitudinally-followed "stroke-belt" cohort$1,144,504
UH3 · FY2018 · NS · contact PI
University of Kentucky Alzheimer's Disease Core Center - Biomarker Core$482,554
P30 · FY2018 · AG · contact PI
Neurovascular astrocyte dysfunction in VCID$375,610
R01 · FY2018 · NS · contact PI
Neurovascular astrocyte dysfunction in VCID$191,250
R01 · FY2018 · NS · contact PI
Small vessel disease biomarkers in a longitudinally-followed "stroke-belt" cohort$707,397
UH2 · FY2017 · NS · contact PI
Neurovascular astrocyte dysfunction in VCID$375,875
R01 · FY2017 · NS · contact PI
Small vessel disease biomarkers in a longitudinally-followed "stroke-belt" cohort$720,022
UH2 · FY2016 · NS · contact PI
Vascular breakdown in Alzheimers Disease with cerebrovascular disease$323,511
R01 · FY2016 · NS · contact PI
Vascular breakdown in Alzheimers Disease with cerebrovascular disease$323,618
R01 · FY2015 · NS · contact PI
Vascular breakdown in Alzheimers Disease with cerebrovascular disease$314,178
R01 · FY2014 · NS · contact PI
Vascular breakdown in Alzheimers Disease with cerebrovascular disease$306,331
R01 · FY2013 · NS · contact PI
Vascular breakdown in Alzheimers Disease with cerebrovascular disease$50,000
R01 · FY2013 · NS · contact PI
Vascular breakdown in Alzheimers Disease with cerebrovascular disease$314,554
R01 · FY2012 · NS · contact PI
Dysregulation of the neurovascular unit in Alzheimer's Disease.$53,354
F32 · FY2009 · AG · contact PI
Dysregulation of the neurovascular unit in Alzheimer's Disease.$51,278
F32 · FY2008 · AG · contact PI
Dysregulation of the neurovascular unit in Alzheimer's Disease.$49,646
F32 · FY2007 · AG · contact PI